Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00661895 · ClinicalTrials.gov registry record · Phase 4

Black Education and Treatment of Hypertension (BEAT HTN)

A Phase 4 study, sponsored by Creighton University.

Completed
Registry status
Phase 4
Development phase
99
Enrollment target

NCT00661895 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 99 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00661895, a Phase 4 study, has completed, sponsored by Creighton University.

COMPLETED
Registry status
Phase 4
Development phase
99 participants
Enrollment target

Study Summary

Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when both control and intervention groups are given free antihypertensive medications and are involved in usual versus intensive intervention strategies. Because of this, it has not yet been determined whether the method of prescribing antihypertensive medications according to JNC 7 guidelines is more, less, or equally as effective as prescribing antihypertensive medications and providing intensive behavioral and clinical interventions. Knowledge in this area of HTN treatment should better able medical and health practitioners to help their AA subjects control HTN. The BEAT Hypertension Clinic will evaluate this method of HTN control by proposing a program that will evaluate the difference in HTN control among subjects receiving usual care and free medications and subjects also receiving free medications, but additionally being treated in a clinic that operates in a more intensive manner in relationship to patient behavior modification, patient-clinician interactions, and physical and social environments. At the conclusion of the study, the BEAT Hypertension Clinic investigators will report findings and help to answer the question of whether medication alone or medication combined with intensive behavioral and clinical treatment is more effective in HTN control in the AA population.

Interventions

  • DRUG Lisinopril
  • DRUG Hydrochlorothiazide
  • DRUG Nifedipine XL
  • DRUG Lisinopril and Hydrochlorothiazide
  • DRUG Metoprolol tartrate

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2005-08
Est. Completion 2009-11
Phase Phase 4

Sponsor

Creighton University

98 total trials

What the Registry Record Tells You About NCT00661895

The ClinicalTrials.gov registry entry for NCT00661895 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Lisinopril is the first listed.

NCT00661895 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00661895 about?

NCT00661895 is a clinical study titled "Black Education and Treatment of Hypertension (BEAT HTN)". Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when both control and intervention groups are given free antihypertensive medications and are involved in usual versus intensive intervention strategies. Because of this, it has not yet been determined whether the...

What is the current status of trial NCT00661895?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 99 participants. The study started on 2005-08. Estimated completion is 2009-11.

What interventions are being tested in trial NCT00661895?

The interventions under investigation include: Lisinopril (DRUG), Hydrochlorothiazide (DRUG), Nifedipine XL (DRUG), Lisinopril and Hydrochlorothiazide (DRUG), Metoprolol tartrate (DRUG).

Who is sponsoring clinical trial NCT00661895?

This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.